Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cell surface expression of CD25 antigen (surface IL-2 receptor α-chain) is not a prognostic marker in chronic lymphocytic leukemia: results of a retrospective study of 281 patients.
Shvidel L, Braester A, Bairey O, Rahimi-Levene N, Herishanu Y, Tadmor T, Klepfish A, Ruchlemer R, Shtalrid M, Berrebi A, Polliack A; Israeli CLL Study Group. Shvidel L, et al. Ann Hematol. 2012 Oct;91(10):1597-602. doi: 10.1007/s00277-012-1492-4. Epub 2012 May 24. Ann Hematol. 2012. PMID: 22623161
Pathogenesis, prevalence, and prognostic significance of cytopenias in chronic lymphocytic leukemia (CLL): a retrospective comparative study of 213 patients from a national CLL database of 1,518 cases.
Shvidel L, Tadmor T, Braester A, Bairey O, Rahimi-Levene N, Herishanu Y, Klepfish A, Shtalrid M, Berrebi A, Polliack A; Israeli CLL Study Group (ICLLSG). Shvidel L, et al. Ann Hematol. 2013 May;92(5):661-7. doi: 10.1007/s00277-012-1663-3. Epub 2012 Dec 29. Ann Hematol. 2013. PMID: 23274356
Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis: a study of 176 patients with prognostic implications.
Tadmor T, Shvidel L, Aviv A, Ruchlemer R, Bairey O, Yuklea M, Herishanu Y, Braester A, Rahimi-Levene N, Vernea F, Ben-Ezra J, Bejar J, Polliack A; Israeli CLL Study Group. Tadmor T, et al. Cancer. 2013 May 15;119(10):1853-9. doi: 10.1002/cncr.27930. Epub 2013 Feb 19. Cancer. 2013. PMID: 23423815 Free article.
Richter's transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study Group.
Tadmor T, Shvidel L, Bairey O, Goldschmidt N, Ruchlemer R, Fineman R, Rahimi-Levene N, Herishanu Y, Yuklea M, Arad A, Aviv A, Polliack A; Israeli CLL Study Group. Tadmor T, et al. Am J Hematol. 2014 Nov;89(11):E218-22. doi: 10.1002/ajh.23826. Epub 2014 Sep 2. Am J Hematol. 2014. PMID: 25110869 Free article.
Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
Herishanu Y, Goldschmidt N, Bairey O, Ruchlemer R, Fineman R, Rahimi-Levene N, Shvidel L, Tadmor T, Ariel A, Braester A, Shapiro M, Joffe E, Polliack A; Israeli CLL Study Group. Herishanu Y, et al. Haematologica. 2015 May;100(5):662-9. doi: 10.3324/haematol.2014.115808. Epub 2015 Feb 6. Haematologica. 2015. PMID: 25661442 Free PMC article.
73 results